[Retracted] Styrylchromones: Biological Activities and Structure-Activity Relationship

Table 10

Summary of the 2-SC in which the antitumoral activity was studied in works using tumor and normal cell lines and description of the observed effects in each type of cells used. The table displays the antitumoral activity shown for the studied 2-SC according to the criterion: selectivity index greater or equal to 2.

2-SC	Studied cell lines		Observed effect(s)	Ref.
	Tumoral	Non-tumoral
1	Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells	HGF, HPC and HPLF cells	Decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells	[64, 66]
30	Ca9-22, HSC-2, HSC-3 and HSC-4 cells		Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells; and apoptosis induction of HSC-2 cells	[66]
56			Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells
57	HSC-2, HSC-3, HSG and HL-60 cells		Decreased cell viability of HSC-2, HSC-3, HSG and HL-60 cells	[64]
58	MCF-7, NCI-H460, Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells	MRC-5 cells, human lymphocytes, HGF, HPLF and HPC cells	Growth inhibition of MCF-7 and NCI-H460 cells; cell cycle arrest at the G2/M phase of MCF-7 and NCI-H460 cells; microtubule-stabilizing antimitotic effect in MCF-7 and NCI-H460 cells; weak inhibition of peripheral human lymphocytes proliferation; decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells; apoptosis induction of HSC-2 cells; DNA fragmentation induction in HL-60 and HSC-2 cells; and activation of caspase 3, 8 and 9 in HL-60 cells	[64–66]
88	Ca9-22, HSC-2, HSC-3 and HSC-4 cells	HGF, HPLF and HPC cells	Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells	[66]
92	Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells		Decreased cell viability of Ca9-22, HSC-2, HSC-3, HSC-4, HSG and HL-60 cells	[64, 66]
103	HSC-2, HSC-3, HSG and HL-60 cells		Decreased cell viability of HSC-2, HSC-3, HSG and HL-60 cells; DNA fragmentation induction in HL-60 and HSC-2 cells; and activation of caspase 3, 8 and 9 in HL-60 cells	[64]
104 - 108	Ca9-22, HSC-2, HSC-3 and HSC-4 cells		Decreased cell viability of Ca9-22, HSC-2, HSC-3 and HSC-4 cells	[66]
110, 111
114, 115
152	AREc32 and K562 cells	Peripheral blood mononuclear cells	Nrf2-inducing activity in AREc32 cells; decreased cell viability and proliferation of K562 cells	[70]

AREc32: human mammary epithelial adenocarcinoma cell line; Ca9-22: human oral squamous cell carcinoma Ca9-22; HGF: human gingival fibroblast; HL-60: promyelocytic human leukaemia-60 cell line; HPC: human pulp cell; HPLF: human periodontal ligament fibroblast; HSC-2: human squamous cell carcinoma-2; HSC-3: human squamous cell carcinoma-3; HSC-4: human squamous cell carcinoma-4; HSG: human submandibular gland carcinoma; K562: human chronic myeloid leukaemia; MCF-7: breast adenocarcinoma cell line; MRC-5: diploid embryonic lung fibroblast cell line; NCI-H460: non-small cell lung cancer; Nrf2: nuclear factor erythroid 2-related factor 2.